Clinical Trials Directory

Trials / Unknown

UnknownNCT02346669

Fecal Microbiota Transplantation for Diabetes Mellitus Type II in Obese Patients

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Tel-Aviv Sourasky Medical Center · Other Government
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The incidence of obesity has dramatically increased during the last three decades, leading to a significant increase of obesity-related morbidity, including type 2 diabetes mellitus (T2DM) that is characterized by resistance of target tissues to insulin action. T2DM obese patients may be treated by medications or by bariatric surgery. Both alternatives have limitations due to incomplete resolution of the diseases, high cost or potential procedural related morbidity. An increasing body of evidence points to a role of the enteric microbiota in the pathogenesis of obesity-related insulin resistance. In addition to that, the gut microbiota is directly affected by the diet composition. Studies in T2DM mice carrying human gut germs, demonstrated special interactions between the gut microbiota and the host, creating a typical microbiota composition which changes significantly following diet change from a western diet, rich with sugar, to a vegetarian diet rich with fibers. This rapid alternations in the microbiota composition has also shown in humans, after changing from western to high fiber diet. A change in diet life style may lead to an improvement in T2DM symptoms such as decrease in visceral adipose tissue.

Detailed description

Study design: 30 Patients will undergo 2 FMT's from a lean donor and will be randomized into 3 types of diet groups: 1. low fat high fiber diet (20% fat) 2. no change in fat intake (sham diet) 3. high fat low fiber diet (40-45% fat) The treating physicians and the patients will be blinded for the diet arm. Before and after FMT, patients will be assessed after an overnight fast (and before taking medications) for weight, anthropometric measures, questionnaires (dietary, general health, antibiotic and probiotic exposure, oral diabetes medication quantity, and other drug exposure), blood and stool. The investigators hypothesize that fecal microbial transplantation from a lean donor to T2DM obese patients, with the combination of low fat high fiber diet, will alter the gut microbiota composition to decrease insulin resistance through microbiota dependent metabolic and immunologic effects.

Conditions

Interventions

TypeNameDescription
PROCEDUREgastroscopyas detailed in arm description
DRUGFecal Microbiota Transplantationas detailed in arm description
OTHERhigh fat low fiber dietas detailed in arm description
OTHERsham dietas detailed in arm description
OTHERlow fat high fiber dietas detailed in arm description

Timeline

Start date
2016-04-01
Primary completion
2018-01-01
First posted
2015-01-27
Last updated
2016-06-09

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT02346669. Inclusion in this directory is not an endorsement.